article thumbnail

DEA Approves Cocaine Derivative for Parkinson’s Research. Why Not Cannabis?

Veriheal

As cannabis enthusiasts, we’re all too familiar with the stigma surrounding its use and the hoops that have to be jumped through to get it into medical research trials. But recent news of the DEA’s approval of a cocaine derivative for Parkinson’s disease research has left us scratching our heads. So what gives?

DEA 98
article thumbnail

DEA Promises Progress on Federal Cultivation Applications, But Provides No Timetable for Action

NORML

The US Drug Enforcement Administration (DEA) has once again pledged to take action to better facilitate clinical cannabis research. In 2016, the DEA similarly announced the adoption of new rules to expand to supply of research-grade cannabis, but failed to take any further action.

DEA 167
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

‘The Doors are Wide Open’: Denver Cannabis Company Gets DEA Approval To Expand Alzheimer’s Research

Cannabis Law Report

The Denver cannabis company MedPharm can now ramp up its research into the effects marijuana has on Alzheimer’s disease. The new DEA research license will now change that. It’s possible because of a new Schedule I Researcher License granted by the Drug Enforcement Administration. credit: CBS). credit: CBS).

DEA 105
article thumbnail

Rod Kight and Shane Pennington Discuss DEA Lawsuit (Video)

Cannabis Law Report

Rod Kight and Shane Pennington discuss the DEA lawsuit about hemp extracts. As many readers of this blog know, the… Read More.

DEA 81
article thumbnail

DEA Proposes Dramatic Increase In Marijuana And Psychedelic Production In 2022, Calling For 6,300 Percent More MDMA Alone

Cannabis Law Report

The Drug Enforcement Administration (DEA) is proposing a dramatic increase in the legal production of marijuana and psychedelics like psilocybin, LSD, MDMA and DMT to be used in research next year. It wants to double the amount of marijuana extracts, psilocybin and psilocyn, quadruple mescaline and quintuple DMT.

DEA 96
article thumbnail

The 2018 Farm Bill Does Not Support the DEA Interim Rule

Canna Law Blog

Unfortunately, the Drug Enforcement Administration (DEA) dropped a surprise interim hemp rule a few weeks ago, which took immediate effect and came as a shock to virtually everyone. The DEA Just Passed a BAD Interim Rule Impacting Hemp CBD and Other Cannabinoids. DEA Interim Final Rule: What Is “Synthetically Derived THC”?

DEA 86
article thumbnail

DEA Interim Final Rule: What Is “Synthetically Derived THC”?

Canna Law Blog

On Friday, the Drug Enforcement Administration (“DEA”) released an Interim Final Rule (the “ Rule ”) that, as we discussed , threatens the hemp industry by treating partially processed hemp extract not intended for consumption (also known as “intermediary hemp”) as a Schedule I controlled substance.

DEA 87